10/537339

PATENT COOPERATION TREATY

PCT/JP2003/015572

10 NOV 2005

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	(PCT A	rticle 36 and Rule 70)	
Applicant's or agent's file reference			
P03-137	FOR FURTHI	ER ACTION	See Form PCT/IPEA/416
International application No.	International fili	ng date (day/month/year)	Priority date (1)
PCT/JP2003/015572	05 Decembe	r 2003 (05 12 2002)	Priority date (day/month/year)
International Patent Classification (II A61K 35/78, 31/122, 31/2	200		06 December 2002 (06.12.2002)
1101K 33/78, 31/122, 31/3	353, 31/355, 31/7016, A	61P 3/06, 3/10, 7/00, 39	/06, 43/00, A23L 1/212, 1/30
Applicant			1,212, 1/30
- Produit	QT D.		
	SUN	STAR INC.	
1. This report is the international	l preliminary examination		
Authority under Article 35 an	id transmitted to the applic	report, established by this cant according to Article 36	International Preliminary Examining
		0	•
and the consists of a fo	otal of 8 sh	eets, including this cover sh	eet.
T and accompanie	ed by ANNEXES, compris	sing:	
a (sent to the applica	nt and to the International	Bureau) a total of	sheets, as follows:
sheets of the	e description alaime		
and/or sheet	s containing rectifications	or drawings which have been authorized by this Authori	en amended and are the basis of this report ity (see Rule 70.16 and Section 607 of the
- Idinimistrat	ive instructions).	-	of the
beyond the	1 supersede earlier sheets, disclosure in the internation	but which this Authority c	considers contain an amendment that goes
Supprement	ai DOX.		modelicu in item 4 of Box No. I and the
o. [(sent to the Inter	national Bureau only) :	a total of (indicate type	and mumbers a
readable form only,	as indicated in the Suppl	taining a sequence listing	and number of electronic carrier(s)) and/or tables related thereto, in computer
Administrative Instru	ictions).	Comental Box Relating to S	and/or tables related thereto, in computer sequence Listing (see Section 802 of the
4. This report contains indications	relating to the following	items:	
Box No. I Basis of t			
Box No. II Priority	as report		
	lishment of out-to-		
Box No. IV Lack of ur	monation of obtainin with i	regard to novelty, inventive	step and industrial applicability
	my of invention		
	statement under Article 35 nd explanations supporting	(2) with regard to novelty,	inventive step or industrial applicability;
Box No. VI Certain do	cuments cited	such statement	industrial applicability;
1 1 =	fects in the international a	** · · ·	
Box No. VIII Certain obs	servations on the international a	oplication	
	servations on the internation	onal application	
te of submission of the demand		Date of completion of the	
30 April 2004 (30.0	4 2004)	Date of completion of thi	
	·	11 Novem	nber 2004 (11.11.2004)
me and mailing address of the IPEA/JP		Authorized officer	, , , , , , , , , , , , , , , , , , ,
			l
simile No.		Telephone No.	. j
m PCT/IPEA/409 (cover sheet) (Janua		- Stophone IVO.	

Translation

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

	PCT/JP2003/015572
1. With regard to the language, this report is based on the interest in the language.	
 With regard to the language, this report is based on the international application in the language indicated under this item. 	anguage in which it was filed, unless
This report is based on translations from the original language into the following which is language of a translation furnished for the purpose of:	ing language
international search (under Rules 12.3 and 23.1(b))	
publication of the international application (under Rule 12.4)	
international preliminary examination (under Rules 55.2 and/or 55.3)	
2. With regard to the elements of the international application, this report is based on furnished to the receiving Office in response to an invitation under Article 14 are referred. The international application as originally filed/furnished the description: pages pages*	(replacement sheets which have been red to in this report as "originally filed" , as originally filed/furnishe
pages* received by this Authority on	, as originary med/furnished
received by this Authority on the claims:	
pages *	an opinio 11. Gt. va
pages* , as amended (toge	, as originally filed/furnishe ether with any statement) under Article
pages*	
received by this Authority on	
the drawings:	
pages	
pages*	, as originally filed/furnished
pages* received by this Authority on	, as originally filed/furnished
pages* received by this Authority on received by this Authority on	
pages* received by this Authority on received by this Authority on	
pages* received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and pages * received by this Authority on	
pages* received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence The amendments have resulted in the cancellation of:	
pages* received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence The amendments have resulted in the cancellation of: the description, pages	
pages* received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence In the amendments have resulted in the cancellation of: the description, pages the claims, Nos	
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence In the description, pages	
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing, pages the description, pages the claims, Nos the drawings, sheets/figs the sequence listing (specify):	
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing, pages the description, pages the claims, Nos the drawings, sheets/figs the sequence listing (specify):	
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence In the description, pages	
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing the description, pages the claims, Nos	uence Listing.
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing the description, pages the claims, Nos	uence Listing.
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify): any table(s) related to sequence disting (specify): this report has been established as if (some of) the amendments annexed to this report has been established as if (some of) the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed, as incommade, since they have been considered to go beyond the disclosure as filed.	uence Listing.
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify): This report has been established as if (some of) the amendments annexed to this report has been considered to go beyond the disclosure as filed, as incomplete the description, pages the claims, Nos. the drawings, sheets/figs the drawings, sheets/figs	uence Listing.
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing the description, pages	uence Listing.
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify): This report has been established as if (some of) the amendments annexed to this report has been considered to go beyond the disclosure as filed, as incomplete the description, pages the claims, Nos. the drawings, sheets/figs the drawings, sheets/figs	
received by this Authority on received by this Authority on a sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing and/or any related table(s) — see Supplemental Box Relating to Sequence listing the description, pages	uence Listing.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

Box No. III Non-establishment of oninion with warreld	PCT/JP2003/015572
and	
The questions whether the claimed invention appears to be novel, to involve an inventive applicable have not been examined in respect of:	step (to be non obvious), or to be industri
the entire international application.	
claims Nos18-23	
because:	
the said international application, or the said claims Nos relate to the following subject matter which does not require an international pre	18-23
SEE SUPPLEMENTAL SHEET	Immnary examination (specify):
the description, claims or drawings (indicate particular elements below) or said clare so unclear that no meaningful opinion could be formed (greater).	aims Nos
are so unclear that no meaningful opinion could be formed (specify):	1.00.
the claims, or said claims Nos.	
by the description that no meaningful opinion could be formed.	are so inadequately supported
no international search report has been established for said claims Nos.	19.00
,	•
the nucleotide and/or amino acid sequence listing does not comply with the standard Administrative Instructions in that:	d provided for in Annex C of the
the waite.	
nas not been furnished	
does not comply with the standard	
the computer readable form has not been furnished	
	
does not comply with the standard	
the tables related to the nucleotide and/or amino acid sequence listing, if in computer the technical requirements provided for in Annex C-bis of the Administrative Instruc	readable form only, do not comply with
see Supplemental Box for further details.	
PCT/IPEA/409 (Box No. III) (January 2004)	

International application No.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT	PCT/JP 03/15572					
Supplemental Box To be used when the space in any of the preceding boxes is not sufficient)						
Continuation of: III. 1.						
The inventions set forth in claim	s 18-23 pertain to					
methods for treatment of the human body by therapy.						
•						
	·					

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP 03/15572

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicabil citations and explanations supporting such statement					
Statement					
Novelty (N)	Claims	4,7,8,11,13,14,17	YES		
	Claims	1-3,5,6,9,10,12,15,16	- NO		
Inventive step (IS)	Claims		- YES		
	Claims	1-17	NO.		
Industrial applicability (IA)	Claims	1-17	- YES		
	Claims		NO		

2. Citations and explanations

- Document 1: JP 2002-119265 A (Sunstar Inc.), 23 April 2002 (Family: none)
- Document 2: JP 2000-169382 A (Sunstar Inc.) 20 June 2000 (Family: none)
- Document 3: JP 2000-300224 A (Nippon Del Monte Corp.), 31
 October 2000 (Family: none)
- Document 4: Oita Nosuisanbutsu Kako Sogo Shido Center Shiken Seiseki Hokokusho, 1997, Vol. 1996, pp. 5-8
- Document 5: Nippon Shokuhin Kagaku Kogaku Kaishi, 1998, Vol. 45, No. 2, pp. 138-144
- Document 6: J. Agric. Food Chem., 1998, Vol. 46, No.10, pp. 4118-4122
- Document 7: Nippon Shokuhin Kagaku Kogaku Kaishi 2001, Vol. 48, No. 4, pp. 246-252
- Document 8: J. Agric. Food Chem. 2002, Vol. 50, No. 23, pp. 6910-6916
- Document 9: JP 11-1686 A (Yoshihide Hagiwara), 6 January 1999; paragraph [0008], (Family: none)
- Document 10: JP 61-112024 A (KK Horiuchi), 30 May 1986 (Family: none)
- Document 11: JP 2002-238536 A (Marine Bio Co., Ltd.), 27
 August 2002 (Family: none)
- Document 12: JP 4-8256 A (Junko Ebata), 13 January 1992

(Family: none)

- Document 13: JP 2000-219880 A (Taiyo Kagaku Co., Ltd.), 8
 August 2000 (Family: none)
- Document 14: JP 2002-308768 A (Fuji Chemical Industry Co., Ltd.), 23 October 2002 (Family: none)
- Document 15: JP 2002-226368 A (Fuji Chemical Industry Co., Ltd.), 14 August 2002 (Family: none)
- Document 16: JP 10-276721 A (Suntory Ltd.) 20 October 1998 (Family: none)
- Document 17: JP 2002-275018 A (Kose Corp.), 25 September 2002 (Family: none)
- Document 18: Shokuhin Kogyo Shidosho Kenkyu Hokoku 2002, Vol. 16, pp. 4-9
- Document 19: JP 2002-153210 A (Yukio Ishikura), 28 May 2002 (Family: None)
- Document 20: JP 2002-360205 A (Kikkoman Corp.), 17

 December 2002 (Family: none)
- Document 21: JP 2002-275076 A (KK Toyo Shin'yaku), 25 September 2002 (Family: none)
- Document 22: JP 2000-229834 A (Kanebo, Ltd.), 22 August 2000 (Family: none)
- Document 23: JP 6-199687 A (Morinaga Milk Industry Co., Ltd.), 19 July 1994 (Family: none)
- Document 24: J. Food Science 2002, Vol. 67, No. 5, pp. 1654-1659
- Document 25: J. Nutrition 2000, Vol. 130, No.9, pp. 2200-2206
- Document 26: J. Agric Food Chem., 1999, Vol. 47, No.4, pp. 1576-1581
- Document 27: Tohoku Nogyo Kenkyu, 1994, No. 47, pp. 317-318
- Document 28: Kyoto-fu Eisei Kenkyu Nenpo, 1986, No. 52, pp. 69-71
- Document 29: JP 2001-299305 A (Bizen Kasei KK), 30 October 2001 (Family: none)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

- Document 30: JP 2002-220340 A (Ito En, Ltd.), 9 August 2002 (Family: none)
- Document 31: JP 2001-270832 A (Ito En, Ltd.), 2 October 2001 (Family: none)
- Document 32: WO 98/33494 A1 (John V. Kosbab), 6 August, 1998; claim 6 & JP 2001-511153 A
- Document 33: Planta, 1999, Vol. 207, No. 4, pp. 604-611

Documents 1-33 above are cited in the international search report.

Documents 1-4 disclose compositions described in claims 1-3 and 5, containing green and yellow vegetables such as broccoli, spinach, parsley and carrots, and light coloured vegetables such as lettuce, cabbage and celery used as food. Document 5 also discloses the fact that aforementioned compositions have antioxidant activity, so that document 5 substantially discloses the inventions set forth in claims 6, 9, 10, 12, 15 and 16. Therefore, the inventions set forth in claims 1-3, 5, 6, 9, 10, 12, 15 and 16 are not novel and do not involve an inventive step.

Documents 5-12, 18, 19 and 29 disclose the fact that the various vegetables cited in claim 2 have antioxidant activity and/or act to lower active oxygen; documents 13-17, 19 and 20-23 disclose the fact that the various constituents cited in claim 4 have antioxidant activity and/or act to lower active oxygen, and documents 21, 30 and 31 disclose the use of antioxidants which include aforementioned constituents in the management of diabetes and/or resulting complications. In addition, documents 26-28 disclose the fact that vegetables cited in claim 2 are rich in vitamin E, and documents 24, 25 and 33 disclose the fact that vegetables cited in claim 2 lower TBARS levels. Moreover, the interrelationships among

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP 03/15572

antioxidant activity, suppression of peroxidized lipid, lowering of active oxygen, vitamin E content and therapeutic effects on TBARS levels or diabetic complications were known in the art before the filing date of the present application. Therefore, given the disclosures in the aforementioned documents of the fact that vegetables cited in claim 2 contain vitamin E and/or flavonoids, or that the aforementioned vegetables have some of the interrelated activities above, such as antioxidant activity, discovery of antioxidant activity, suppression of peroxidized lipid, lowering of active oxygen, vitamin E content and therapeutic effects on TBARS levels or diabetic complications in each of the vegetables is an option within the ordinary competence of a person skilled in the art. Moreover, the description does not appear to describe any marked effect due to combining the constituents mentioned above. Therefore, the inventions set forth in claims 1-17 do not involve an inventive step, because they could be deduced easily by a person skilled in the art with reference to the art disclosed in documents 1-33 above.